At the news
? NEUTRALIMPACT 3/10 144 filed Apr 15, 2026 at 16:41 ET
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to notify the SEC of his intent to sell 1,300 shares of common stock, representing a small portion of his holdings. This is part of a broader 10b5-1 trading plan, following a series of prior sales totaling over $14.6M in the past month.
- Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose selling 1,300 shares.
- The shares are common stock, to be sold on or after April 15, 2026, via Morgan Stanley Smith Barney LLC.
- This filing is part of an existing 10b5-1 plan, with recent sales by Chadwick totaling approximately $14.6 million over the past month.
- The proposed sale is relatively small compared to prior transactions and the company's $7.3B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access